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Purpose: Since electroporation (EP) can increase the permeability of biological membranes, 
we hypothesized that it offers an opportunity to enhance the transdermal delivery of drugs for 
intra-articular indications. Our aim was to compare the anti-inflammatory and analgesic efficacy 
of EP-combined topical administration of diclofenac sodium hydrogel (50 mg mL-1 in 230 µL 
volume) with that of an equivalent dose of oral (75 mg kg-1) and simple topical administration.
Methods: Arthritis was induced with the injection of 2% λ-carrageenan and 4% kaolin into 
the right knee joints of male Sprague Dawley rats. EP was applied for 8 min with 900 V high-
voltage pulses for 5 ms followed by a 20 ms break. Drug penetration into the synovial fluid and 
plasma was detected by high-performance liquid chromatography. Leukocyte–endothelial inter-
actions were visualized by intravital videomicroscopy on the internal surface of the synovium. 
Inflammation-induced thermal and mechanical hyperalgesia reactions, knee joint edema, and 
inflammatory enzyme activities were assessed at 24 and 48 h after arthritis induction.
Results: EP significantly increased the plasma level of diclofenac as compared with the topi-
cal controls 10 min after the 2% λ-carrageenan and 4% kaolin injection. Increased leukocyte– 
endothelial interactions were accompanied by joint inflammation, which was significantly reduced by 
oral and EP diclofenac (by 45% and by 30%, respectively) and only slightly ameliorated by simple 
topical diclofenac treatment (by 18%). The arthritis-related secondary hyperalgesic reactions were 
significantly ameliorated by oral and EP-enhanced topical diclofenac treatments. The knee cross-
section area (which increased by 35%) was also reduced with both approaches. However, simple 
topical application did not influence the development of joint edema and secondary hyperalgesia.
Conclusion: The study provides evidence for the first time of the potent anti-inflammatory 
and analgesic effects of EP-enhanced topical diclofenac during arthritis. The therapeutic benefit 
provided by EP is comparable with that of oral diclofenac; EP is a useful alternative to conven-
tional routes of administration.
Keywords: diclofenac, transdermal delivery, HPLC, intravital videomicroscopy
Introduction
Arthritis is a collective term encompassing many diseases with distinct etiologies 
but common symptoms, such as joint pain and inflammation. Owing to its high 
incidence, it is of significant public health and economic importance, yet therapeutic 
options are limited to pain relief and reduction of inflammation.1,2 Today, the “gold 
standard” therapy for alleviating arthritis-related pain is diclofenac, a nonsteroidal 
anti-inflammatory drug (NSAID) of the phenylacetic acid class.3,4
Unfortunately, the side effects of such an effective compound are also signifi-
cant. Diclofenac usages are associated with the NSAID category risk of dose-related 
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gastrointestinal, cardiovascular, and renal adverse effects; 
topical preparations were thus developed to limit the 
potentially serious complications of systemic treatments. 
Diclofenac is a lipophilic organic acid, but formulations with 
salts are water-soluble, and this property renders the com-
pound capable of penetrating the skin and the synovial lining 
of diarthrodial joints. The systemic absorption of topically 
administered diclofenac is 3%–5% of that of oral products, 
and the dosage reaches the site of action ten times later as 
compared with that of an equivalent oral dose.5,6 On the whole, 
since passive transdermal passage after topical administrations 
is rather slow and therapeutic drug levels cannot always be 
reached, new delivery methods are needed to achieve locally 
effective drug concentrations directly at the application site.7
Various skin penetration techniques have been developed 
to improve transdermal drug delivery and bioavailability, 
including ultrasound and electroporation (EP).8–14 With EP, 
applications of short, high-voltage pulses cause transitory 
structural perturbations in the lipid bilayer of the membranes. 
Lipophilic or hydrophilic molecules, neutral or highly 
charged compounds, can thus be transported through or into 
membranes of bacteria or mammalian cells, if they are up to 
40 kDa in molecular weight.15 Common fields of indication 
for EP are biological and artificial membranes, but complex 
structures such as the stratum corneum or the synovium can 
also be targeted.16,17
Based on this background, we hypothesized that EP can 
amplify the transport of topical diclofenac into the joints, and 
thus the effectiveness of local administration increases. The 
aims were to compare the penetration properties of diclofenac 
hydrogel into the synovial fluid after different administration 
routes and to estimate the analgesic and anti-inflammatory 
reactions after oral and topical drug deliveries in a standard-
ized rat model of carrageenan/kaolin (C/K)-induced knee 
joint monoarthritis.
Materials and methods
The experiments were performed on male Sprague Dawley 
rats (average weight 300±50 g). The animals were housed 
in plastic cages in a thermoneutral environment and pro-
vided standard laboratory chow and water ad libitum. The 
experimental protocol complied with EU Directive 2010/63 
for the Protection of Animals Used for Scientific Purposes 
and was approved by Hungary’s National Scientific Ethical 
Committee on Animal Experimentation (National Competent 
Authority) under license number V./148/2013. This study also 
satisfied the criteria in the US National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals.
arthritis induction
For arthritis induction, the animals were anesthetized with 
intraperitoneal (IP) ketamine (50 mg kg-1) and xylazine 
(12 mg kg-1), and the skin over the knees was disinfected 
with povidone iodide. Then a single intra-articular injection 
of a 75 µL mixture of 2% λ-carrageenan (Sigma-Aldrich, 
St Louis, MO, USA) and 4% kaolin in saline was adminis-
tered to the right knee joint.18,19 The contralateral knee was 
injected with saline.
experimental protocols
The goal of the first experimental series was to assess the 
serum and the synovial concentrations of diclofenac by high-
performance liquid chromatography (HPLC). The animals 
were anesthetized with IP sodium pentobarbital (45 mg kg-1) 
and placed in a supine position on a heating pad to main-
tain body temperature between 36°C and 37°C. In the first 
group (n=16), diclofenac sodium gel (50 mg mL-1 in 230 µL 
volume) was applied topically above the knee joint. In the 
second group (n=16), after dispersion of the diclofenac gel 
over the knee joint, EP was applied for 8 min. Samples of 
blood from the inferior vena cava and of synovial washing 
fluid from the knee joint were collected at 10, 30, 60, and 
120 min of the experiment. The samples were frozen at -80°C 
until the HPLC measurement. At the end of the last sampling 
point, the animals were sacrificed with a single overdose of 
anesthetic (Figure 1).
In the second series of experiments, inflammation-related 
changes to the synovial microcirculation were evaluated 
directly by intravital videomicroscopy (IVM). The animals 
were anesthetized with IP sodium pentobarbital (45 mg kg-1) 
and divided into four groups according to the administra-
tion route of diclofenac: The animals were treated with 
per os diclofenac (75 mg kg-1 diclofenac sodium, Novartis 
Hungaria Kft., Budapest, Hungary) in Group 1 (n=6), with 
topical diclofenac gel (50 mg mL-1 in 230 µL volume; n=6) 
in Group 2, and with EP-combined topical diclofenac gel 
(50 mg mL-1 in 230 µL volume; n=6) in Group 3. Group 4 
served as a per os saline-treated control (n=6). The treatments 
were always applied 2 h before (t= -2 h) and 2 h after (t=2 h) 
the arthritis induction (Figure 1).
In the third experimental series, the effectiveness 
of different routes of diclofenac treatment on nocicep-
tion and inflammatory edema formation was compared 
in C/K-induced arthritis. The animals were divided into 
four groups (n=6) according to the administration route of 
diclofenac: 1) per os diclofenac sodium, 2) topical diclofenac 
gel, 3) EP-enhanced topical diclofenac gel, and 4) sham 
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(per os saline-treated). Treatments were applied twice 
daily (every 12 h). The nociceptive tests were performed 
24 h after the C/K injection, while knee joint swelling was 
evaluated at the peak of edema formation 48 h after arthritis 
induction. At the end of the experiments, the animals were 
anesthetized with IP sodium pentobarbital (45 mg kg-1) for 
sample taking and thereafter sacrificed with a single overdose 
of anesthetic. Synovial washing fluid samples and synovium 
tissue specimens were collected for biochemical measure-
ments and histology. Tissue biopsies were stored at -20°C 
until the examinations (Figure 1).
Diclofenac-containing hydrogel 
formulation
The hydrogel was prepared using the following procedure. 
Five w/w% diclofenac sodium (Sigma-Aldrich) was dis-
solved in a mixture of purified water and 30 w/w% ethanol 
(Sigma-Aldrich). Two w/w% hydroxypropyl methylcellulose 
(METHOCEL E4M Premium, Dow Chemical, Midland, 
MI, USA) was added to this solution. The pH value was 
adjusted to 8.0±0.1 to ensure the dissolution of the active 
substance by adding triethanolamine (2 w/w% solution, 
Hungaropharma Ltd., Budapest, Hungary) if necessary 
(Supplementary materials).
electroporation protocols
The noninvasive skin EP treatment was performed with 
a Mezoforte Duo Mez 120905-D instrument (Dr Derm 
Equipment Ltd., Budapest, Hungary). A polypropylene-
covered treating handpiece with a 25 mm diameter plate 
electrode was used (modulation with 900 V pulses, a 5 ms 
voltage pulse was followed by a 20 ms break). Two hundred 
thirty µL diclofenac hydrogel was used, and the EP treatment 
time was 8 min.
hPlc measurements
The synovial washing fluid and plasma samples were analyzed 
using an Agilent HPLC system (Agilent Technologies, 
Palo Alto, CA, USA) equipped with an automated sol-
vent delivery system, which has an integrated degasser 
(1260 Infinity Quaternary Pump, Agilent Technologies), an 
Agilent 1260 Infinity autosampler (Agilent Technologies) 
and a 1024-element diode array detector (1260 Infinity 
Diode Array Detector, Agilent Technologies). The system 
control and data acquisition were performed with Agilent 
ChemStation B.04.03 software (Agilent Technologies). 
The chromatographic parameters and the sample extraction 
procedure have been provided in the Supplementary 
materials.
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PLQ       
' '&. ' ' ' 6
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' '&.
±   K,90
6HULHV
Figure 1 Time sequence of interventions.
Notes: In the first series, the diclofenac concentration in the serum and the synovial washing fluid was measured by HPLC. In the second experimental series, tests for 
secondary mechanical touch sensitivity and heat-provoked paw withdrawal were performed 24 h after arthritis induction with c/K and for knee joint swelling measurements 
48 h after the challenge. In the third series, IVM examinations of the synovial membrane were performed 6 h after the challenge.
Abbreviations: c/K, carrageenan/kaolin; D, diclofenac treatment; hPlc, high-performance liquid chromatography; iVM, intravital videomicroscopy; s, sample taken.
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nociceptive tests
Mechanical hyperalgesia was quantified using a plantar aes-
thesiometer (Dynamic Plantar Aesthesiometer mod-37450; 
UgoBasile, Comerio, Italy) and was expressed as paw with-
drawal thresholds. Thermal hyperalgesia was detected with the 
paw withdrawal test using a Hargreaves apparatus.20 Baseline 
measurements were performed before the induction of arthri-
tis, while the development of inflammation was investigated at 
the peak of nociceptive sensitivity 24 h after C/K injection.
Knee joint swelling (morphological 
assessment)
Joint inflammation was characterized by the changes in the 
diameter of the joints 48 h after C/K injection. The antero-
posterior and mediolateral diameters were measured with a 
caliper square, and the cross-sectional area was calculated.
analysis of gastric effects
Gastric lesions potentially associated with diclofenac tox-
icity were assessed at 48 h. After retrieving and washing 
with saline, photographs were taken of the freshly prepared 
stomachs. The location (near the pylorus, lesser curvature 
of the fundus, or diffuse) was recorded, and the extent of 
the lesions was evaluated by planimetric analysis using the 
ImageJ software (National Institutes of Health, Bethesda, 
MD, USA).
synovial sampling
The skin over the knee was disinfected with povidone iodide, 
and 75 µL PBS was injected into the knee to collect synovial 
fluid. The fluid was centrifuged at 4°C for 5 min at 4,000 g 
in Eppendorf tubes. Then the samples were frozen at -80°C 
until they could be tested.
TnF-α levels
The cytokine content of the synovial washing fluid was 
measured with commercially available enzyme-linked immu-
nosorbent assay kits (Quantikine Ultrasensitive ELISA kit; 
Biomedica Hungaria Ltd., Budapest, Hungary).
MPO activity
Tissue MPO activity was measured in synovium and perio-
steum biopsies using the method developed by Kuebler 
et al.21 Briefly, the tissue was homogenized with Tris-HCl 
buffer (0.1 M, pH 7.4) containing 0.1 M polymethylsulfonyl 
fluoride to block tissue proteases and then centrifuged at 4°C 
for 20 min at 24,000 g. The MPO activities of the samples 
were measured at 450 nm (UV-1601 spectrophotometer; 
Shimadzu, Kyoto, Japan), and the data were corrected for 
the protein content.
XOr activity
Tissue biopsies were homogenized in a phosphate buffer 
(pH 7.4) containing 50 mM Tris-HCl, 0.1 mM EDTA, 
0.5 mM dithiotreitol, 1 mM phenylmethylsulfonyl fluoride, 
10 µg mL-1 soybean trypsin inhibitor, and 10 µg mL-1 
leupeptin. The homogenate was centrifuged at 4°C for 20 min 
at 24,000 g, and the supernatant was loaded into centrifugal 
concentrator tubes. The activity of XOR was determined in 
the ultrafiltered supernatant by fluorometric kinetic assay 
based on the conversion of pterine to isoxanthopterine in 
the presence (total XOR) or absence (XOR activity) of the 
electron acceptor methylene blue.22
surgical procedure for the iVM 
examinations
A detailed description of the surgical procedure can be found 
elsewhere. In brief, the animals were anesthetized with IP 
sodium pentobarbital (45 mg kg-1) 6 h after the intra-articular 
C/K injection.23 The jugular vein was cannulated for further 
supplementary doses of anesthetic. Cannulation of the trachea 
maintained the patent airway, and the arterial pressure was 
monitored through a carotid artery cannule (Statham P23Db 
transducer; Experimetria Ltd., Budapest, Hungary). The 
animals were placed on a specially designed heating pad in 
a supine position for the IVM examination, during which the 
slightly flexed knee joint of the hind limb was opened with 
a microsurgical technique. Surgical preparation included a 
longitudinal skin incision and a transverse cut of the quad-
riceps femoris tendon. After a circumferential cut on the 
joint capsule, the patella was turned aside, and the synovial 
membrane on the medial condyle of the tibia was visible.
iVM examinations
Synovial microcirculation was investigated by means of 
fluorescent IVM (Zeiss Axiotech Vario 100 HD microscope, 
100 W HBO mercury lamp, Acroplan 20× water immersion 
objective), while the synovial membrane was superfused 
with 37°C saline. Erythrocytes were labeled with fluores-
cent isothiocyanate (0.2 mL intravenously, Sigma-Aldrich 
Chemicals) and leukocytes were stained with rhodamine-6G 
(0.1 mL intravenously, Sigma-Aldrich).
Video analysis
IVM records were analyzed offline and frame-to-frame 
using image analysis software (IVM, Pictron Ltd., Budapest, 
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Hungary). Polymorphonuclear leukocytes (PMNs) were defined 
as cells adherent (stickers) to the endothelial lining within an 
observation period of 30 s. The number of adherent cells per 
mm2 of endothelial surface was counted in 5 postcapillary 
venules (diameter ranges from 11 to 15 µm) per animal.
statistical analysis
Data analysis was performed with the SPSS 17.0 software 
(SPSS Inc., Chicago, IL, USA). Changes in variables within 
and between groups were analyzed by two-way analysis 
of variance, followed by the Holm–Sidak test. All data 
are expressed as means ± standard deviation of the mean. 
P-values ,0.05 were considered statistically significant.
Results
Plasma and synovial diclofenac 
concentrations
The plasma and the serum concentrations of diclofenac 
were the highest 10 min after the EP treatment; they then 
decreased at 30 min and remained constant at 60 and 120 min. 
EP-enhanced diclofenac delivery exhibited a significantly 
higher plasma level of diclofenac as compared with the 
simple topical application 10 min after the application 
(Figure 2). There were no significant differences in the 
diclofenac content of the synovial fluid and the plasma after 
the EP-combined application. However, simple topical appli-
cation did not result in detectable diclofenac content in the 
synovial fluid at the same point in time (Figure 2).
leukocyte–endothelial interactions
In the second experimental series, the microcirculatory 
consequences of the joint inflammation were quantified via 
IVM, and the PMN–endothelial interactions (rolling and 
sticking) in the postcapillary venules of the synovial mem-
brane were determined. The rolling fraction of the PMNs in 
the postcapillary synovial venules exhibited a large degree 
of dispersion, and no baseline differences were observed 
between the C/K- and saline-injected knees or between the 
groups which participated in the treatment protocols (data not 
shown). However, the injection of C/K was accompanied by 
a statistically significant increase in PMN adherence (stick-
ing) to the endothelial layer as compared to the control side 
(Figure 3). This reaction was considerably reduced with the 
administration of oral diclofenac. However, it was only mod-
erately ameliorated by the EP-enhanced diclofenac hydrogel, 
and there were no changes in response to the simple topical 
application of the hydrogel.
Inflammatory enzyme activities and 
cytokine production
XOR activity was significantly increased in response to 
arthritis induction, in comparison with the saline-injected 
knee joint. These values were significantly decreased when 
diclofenac was applied orally or topically (Figure 4A).
In the C/K-injected limbs, the MPO activity of the syn-
ovial tissue was significantly increased as compared with 
that of the saline-injected controls. In the oral diclofenac and 
EP-enhanced topical diclofenac-treated groups, MPO activ-
ity was significantly lower than in the nontreated animals. 
However, conventional topical treatment did not influence 
the increased MPO activity (Figure 4B).
The C/K injection resulted in a significant increase in 
TNF-α concentration in the synovial lavage fluid, which was 
diminished by both the oral intake and EP-enhanced topical 
treatment (Figure 4C).
Nociception and inflammatory edema
In the third series, the extent of inflammation was estimated 
with functional tests 24 h after arthritis induction. The 
mechanical touch sensitivity was considerably increased in 
response to arthritis as the C/K-injected limbs responded to 
a lower level of trigger than the saline-injected control limbs 
in animals receiving the saline vehicle (Figure 5A). This 
parameter was significantly diminished in response to oral 
and EP-enhanced topical diclofenac treatments, albeit that 
complete restoration was not achieved. The thermal nocice-
ptive latency (Figure 5B) was also significantly decreased 
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Figure 2 Diclofenac concentrations in the serum (black columns) and the synovial 
washing fluid (gray columns) measured by HPLC (Series 1).
Notes: Diclofenac sodium gel was applied topically above the knee joint (topical), or 
eP was applied for 8 min over the knee joint (eP) after the diclofenac gel dispersed. 
Samples of blood and synovial washing fluid were collected 10 min after application. 
Data are presented as means ± sD. #p,0.05 vs serum level (two-way anOVa and 
holm–sidak test).
Abbreviations: anOVa, analysis of variance; eP, electroporation; hPlc, high-
performance liquid chromatography; sD, standard deviation of the mean.
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Figure 3 The effects of diclofenac treatments on the number of rolling (A) and sticking (B) leukocytes in the postcapillary venules of the synovial membrane (series 3).
Notes: Knees were injected with c/K (black columns), or contralateral knees were treated with a saline vehicle (white columns). Data are presented as means ± sD. #p,0.05 
vs control limb; *p,0.05 vs c/K + oral saline (two-way anOVa and holm–sidak test).
Abbreviations: anOVa, analysis of variance; c/K, carrageenan/kaolin; sD, standard deviation of the mean.
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Figure 4 The effects of diclofenac treatments on the c/K-induced changes in MPO activity (A), XOr activity (B), and TnF-α levels (C) (series 2).
Notes: Knees were injected with c/K (black columns), or contralateral knees were treated with a saline vehicle (white columns). Data are presented as means ± sD. #p,0.05 
vs control limb; *p,0.05 vs c/K + oral saline (two-way anOVa and holm–sidak test).
Abbreviations: anOVa, analysis of variance; c/K, carrageenan/kaolin; sD, standard deviation of the mean.
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in the injured leg in the saline-treated group, and oral and 
EP-enhanced topical diclofenac treatments exerted similar 
protective effects to those seen with the von Frey test.
The changes in knee cross-section (Figure 5C) furnish 
a direct and objective measure of joint inflammation. 
The cross-sectional area in the C/K-injected knees was 
significantly enlarged 48 h after the challenge but was sig-
nificantly reduced by both the conventional topical and the 
EP-enhanced topical diclofenac treatments. In the case of 
oral diclofenac administration, complete restoration to the 
level for the saline-injected knees was achieved.
adverse effects of diclofenac intake
The gastric adverse effects of diclofenac intake were assessed 
by planimetric analysis of ulcers in the gastric mucosa. The 
topically applied diclofenac sodium with or without EP 
had no deleterious effect on gastric mucosa; however, an 
equivalent dose of oral diclofenac sodium resulted in ulcer 
formation in 70% of the animals. The location of gastric 
ulcerations in the rat stomach was variable and included only 
mild lesions with edema, irritation, and petechia formation 
(Supplementary materials; Figure S1).
Discussion
This study has demonstrated the added value of EP to the 
transdermal delivery of diclofenac into the knee joint in 
experimental arthritis. The analgesic effect of EP-enhanced 
delivery was comparable to that of the oral administration 
and manifested in decreased nociceptive sensitivity, reduced 
joint swelling, and lower cytokine concentration in the syn-
ovial fluid and lower inflammatory enzyme activities in the 
synovial tissue. The EP treatment also influenced the number 
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Figure 5 The effects of diclofenac treatments on the c/K-induced changes in mechanical touch sensitivity (A), heat-provoked paw withdrawal latency (B), and changes in 
knee joint swelling (C) (expressed as a knee cross-section) (series 2).
Notes: Knees were injected with c/K (black columns), or contralateral knees were treated with a saline vehicle (white columns). Data are presented as means ± sD. #p,0.05 
vs control limb; *p,0.05 vs c/K + oral saline (two-way anOVa and holm–sidak test).
Abbreviations: anOVa, analysis of variance; c/K, carrageenan/kaolin; sD, standard deviation of the mean.
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of PMN–endothelial interactions at the level of the synovial 
microcirculation.
Following oral administration, diclofenac absorbs rapidly 
through the gastrointestinal tract. However, due to first-pass 
metabolism, only 60% of the dose reaches the systemic 
circulation, where it bonds extensively to plasma proteins, 
mainly albumin.24 Substantial concentration of the drug is 
attained in synovial fluid, which may be one of the sites of 
action of diclofenac. It has been shown that the antinocicep-
tive and anti-inflammatory action of diclofenac is directly 
proportional to its concentration in the synovial fluid.25 
Diclofenac has a short biological half-life (approx 2 h) and 
is eliminated following biotransformation to glucuroconju-
gated and sulfate metabolites, which are excreted in urine.26 
The pharmacological action of oral drugs depends on the 
absorption into the circulation and subsequent distribution 
to the peripheral tissues; in contrast, efficacy of topical drugs 
relies on penetration through the skin.
EP is promising among skin penetration enhancement 
techniques; apart from transdermal delivery, application 
of EP has been widely investigated in cell biology, 
biotechnology, and electrochemotherapy.13,14,16 EP applies 
high-voltage pulses to the biological membranes and results 
in conformation changes in their stereo structures. Transder-
mal drug penetration into the joint cavity is mostly limited 
by the low permeability of the stratum corneum of the skin, 
the thickness of the surrounding tissue layer, and the special 
physicochemical barrier function of the synovial membrane, 
which is commonly referred to as the “blood–joint barrier.”27 
However, EP is capable of opening transitory pores on 
complex structures, such as the multilamellar lipid bilayer 
of the stratum corneum and the synovial membrane.28,29 
Macromolecules of up to 40 kDa can thus be transported 
through and/or into the skin.11,15
Electroporation is now widely used as an alternative 
to small interfering RNA or naked DNA delivery for 
targeted suppression of therapeutic genes into the knee 
joint in arthritis.30,31 However, electrotransfer of painkiller 
drugs into the knee joint is less widespread.32 According 
to a recent review, plasma levels of diclofenac after topical 
administration decrease from 0.2% to 8% of those after oral 
administration.33 Unfortunately, the resultant synovial con-
centration is also decreased, as compared to an equivalent 
oral dose. Effective concentrations in target tissues can be 
augmented with EP.32 In accordance with literature data, our 
results revealed that EP causes higher concentration values 
in the serum as compared with the topical administration. 
The diclofenac concentration in the synovia was equal to 
the serum concentrations; however, conventional topical 
treatment did not result in a detectable amount of diclofenac 
sodium in the synovial fluid.
Intra-articular injection of C/K is a well-established model 
of an acute onset monoarthritis resembling osteoarthritis. 
In this model, arthritis is probably initiated by mechanical 
damage to the inner surface of the synovium resulting in 
an inflammatory response indirectly to the activation of the 
endothelial side of the synovial barrier. It is characterized by 
an initial nonphagocytic edema and rapid uptake of the late 
phagocytic inflammatory phase, where PMNs accumulate 
in the affected area.19,34 It has been demonstrated that PMNs 
are primed within 1 h and are in the majority up to 12 h 
after the arthritis induction; subsequently, they are replaced 
by predominating macrophages until the resolution of the 
inflammation at 48 h.27 It has also been found that the rate 
of PMN infiltration is directly related to severity of inflam-
mation in the synovial membrane.35,36 Based on the pivotal 
role of PMNs in the initiation and maintenance of joint dis-
orders, we employed the PMN-derived experimental model 
of inflammatory arthritis in these studies.
Adhesive cell-to-cell interactions are regulated by β2 
integrins (CD11/CD18) expressed on PMNs and their 
associated endothelial ligands (ICAMs and VCAMs).37 The 
presence of adhesion molecules on postcapillary endothelial 
cells in the inflammatory synovial microenvironment has 
previously been shown and proven to be an appropriate 
marker for estimating inflammation.23,38,39 These reactions 
can be quantitatively assessed by IVM, and the efficacy 
of various therapeutic interventions can also be judged 
objectively. PMN accumulation peaks very early, usually at 
6–8 h in this model, and (at approx 24 h) macrophages pre-
dominate in the exudates thereafter.40 Like other nonselective 
cyclooxygenase inhibitors, diclofenac diminishes the number 
of PMN–endothelial interactions.41,42 Sticking in the synovial 
vessels was considerably reduced with the oral administration 
of diclofenac. However, it was only moderately ameliorated 
by the EP-enhanced diclofenac hydrogel, and there were no 
changes in response to the simple topical application of the 
hydrogel.
Administration of C/K injection into the knee joint results 
in primary and secondary hyperalgesia in the inflammatory 
monoarthritis.43 Secondary hyperalgesia develops at the 
paw to heat and mechanical stimuli, and primary hyperal-
gesia is present over the inflamed knee joint.44,45 Secondary 
hyperalgesia develops as a result of the sensitization of the 
dorsal horn neurons neighboring the spinal representation 
of the injured tissue.46 Secondary hyperalgesia reactions 
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were investigated at the peak of the joint inflammation and 
demonstrated a significant amelioration as a consequence of 
diclofenac treatment.47 Like the oral diclofenac treatment, 
EP completely restored thermal nociceptive sensitivity 
and increased mechanical touch sensitivity, but to a lesser 
extent. Knee swelling, which is an objective parameter of 
joint inflammation, was significantly reduced with both the 
oral and the EP-enhanced diclofenac treatment.48 Again, this 
increased volume was significantly reduced by both oral 
and EP-enhanced diclofenac treatments 48 h after arthritis 
induction.
The C/K-induced arthritis is also an appropriate model for 
the evaluation of the analgesic and anti-inflammatory proper-
ties of diclofenac. The TNF-α response is an early marker 
in carrageenan-induced inflammation, and thus the changes 
were measured in the synovial fluid 48 h after intra-articular 
C/K or saline injections. Free radical formation has been 
demonstrated in the synovial fluid and synovial membrane 
under clinical conditions and proposed as a causative factor 
in joint disorders.22,49 Specifically, oxidoreductive stress has 
been shown to play a fundamental role in the pathogenesis 
of arthrosis as a result of increased pressure in the synovial 
cavity, reduced capillary density and vascular changes, and 
due to the increased metabolic rate of synovial tissue in 
joint inflammation.50–52 Being a source of the oxygen free 
radical formation located in synovial cells, XOR activity has 
been shown to increase in joint inflammation.36,53 Moreover, 
joint inflammation was also associated with enhanced XOR 
activity in the synovial fluid.54 Our present findings dem-
onstrated increases in XOR activity in response to arthritis 
attenuated by diclofenac treatment, applied either by oral 
or simple topical routes of administration, the latter being 
more accentuated in the case of EP. PMNs are also important 
sources of free radicals through their NADPH oxidase 2 
activities.55 As for microcirculatory inflammatory reactions 
induced by inflammation, the increase in both the primary 
and secondary forms of PMN–endothelial interactions 
(rolling and firm adherence) were confined to the periosteal 
postcapillary venules. In this model, C/K-induced mono-
arthritis was the positive control. This aggressive arthritis 
model, which is associated with severe tissue destruction, 
is also known to be mediated by infiltrating PMNs.19,23 Data 
regarding the final step of PMN–endothelial interactions (ie, 
sticking) were well correlated with the tissue accumulation 
of PMNs, as determined by MPO activity. Diclofenac treat-
ment attenuated the MPO activity in the inflamed synovial 
tissue, applied either via oral or EP-enhanced topical routes 
of administration.
The present study has provided evidence for the direct 
action of EP-enhanced transdermal diclofenac sodium 
delivery on the synovial microcirculation as proven by the 
decreased rolling and the reduced sticking of leukocytes. 
The biochemical measurements also demonstrated that 
diclofenac achieved an efficient tissue concentration in the 
synovium since inflammatory enzyme activities decreased. 
In summary, EP-enhanced transdermal diclofenac sodium 
delivery attenuated the microcirculatory deterioration and the 
consecutive stages of tissue inflammation; therefore, this type 
of mechanism might be an interesting focus for therapeutic 
strategies in arthritis.
Conclusion
EP-enhanced diclofenac delivery is well tolerated and 
possesses superior efficacy compared to simple topical 
application in experimental arthritis. The plasma and the 
joint concentrations of EP diclofenac are similar to those 
in oral administration. Further investigations are needed to 
determine the optimal parameters of EP and to diminish the 
plasma level of diclofenac.
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Supplementary materials
characterization of the diclofenac 
sodium-containing hydrogel
Rheological investigations and pH measurements were 
designed to characterize the hydrogel.
The pH of the semisolid formulations was measured with 
a Testo 206 pH meter (Testo SE & Co. KGaA, Lenzkirch, 
Germany). The probe of the device was immersed into 
three different parts of the sample. The pH was adjusted 
to 8.0±0.1.
The rheological properties were studied with a Physica 
MCR101 rheometer (Anton Paar, Graz, Austria). The mea-
suring device was of the parallel plate type (with a 25 mm 
diameter and a gap height of 0.10 mm). The flow and viscos-
ity curve were recorded over the shear rate range from 0.1 
to 100 and from 100 to 0.1 s-1 at 32°C.
The flow curve of the gel can provide information on 
the viscosity changes under flow conditions and on the time 
dependency of the structure breakdown and recovery.
The flow curve of the gel presented shear thinning behav-
ior, which means that the shear stress continuously increases 
with the shear rate, but the rate of the increase decreases. The 
curves showed slight thixotropy, which means the structure 
regeneration is time-dependent.
high-performance liquid chromatography 
(hPlc) measurements of the synovial 
washing fluid and plasma samples
The quantitative measurement of diclofenac sodium was 
carried out with the HPLC method.
chemicals and reagents for hPlc
Methanol, orthophosphoric acid (85% v/v), potassium dihy-
drogen phosphate, isopropanol, and n-hexane were bought 
from VWR International GmbH (Darmstadt, Germany). All 
reagents and solutions used were analytical grade, except the 
methanol, which was HPLC grade. The purified water for the 
HPLC was acquired from TKA Smart2Pure device (TKA, 
Burladingen, Germany).
hPlc system and conditions
The HPLC analysis of diclofenac sodium was conducted 
using an Agilent HPLC system (Agilent Technologies, 
Palo Alto, CA, USA) equipped with an automated solvent 
delivery system, which has an integrated degasser (1260 
Infinity Quaternary Pump, Agilent Technologies), an Agilent 
1260 Infinity autosampler, and a 1024-element diode array 
detector (1260 Infinity Diode Array Detector, Agilent Tech-
nologies). The system control and data acquisition were 
performed with Agilent ChemStation B.04.03 software 
(Agilent Technologies). The chromatographic parameters 
are provided in Table S1.
The chromatographic separations were performed on 
Kromasil® 100 5C188 (250×4, 6 mm ID, 5 µm) (Phenomenex 
Inc., Torrance, CA, USA) analytical column. The column 
temperature was maintained at a constant 35°C. Separa-
tions were performed in gradient mode. The mobile phase 
was eluted at a flow rate of 1.5 mL min-1, and effluent was 
monitored at 254 nm.
The mobile phase consisted of two components. Compo-
nent A was a mixture of methanol and PBS buffer at a ratio 
of 80:20 volume/volume percentage (potassium hydrogen 
phosphate, 5 mM and diluted orthophosphoric acid buffer, 
5 mM, pH 2.5, adjusted by adding 85% orthophosphoric 
acid). Component B was a 20:80 (v/v) mixture of methanol 
and PBS buffer.
The preliminary ratio was 30:70 (v/v) A:B for 1 min; 
then the volume for B was increased from 70% to 100% 
after 4.1 min and sustained for 1 min before being returned 
to the initial conditions after 5 min. After a measurement, 
2 min at 154 bar pressure for equilibration of the column 
was performed before the next injection. The retention 
time for diclofenac sodium was 4.5±0.054 min (relative 
standard deviation =0.29%) (Table S1).
Preparation of standard solutions and calibration 
samples
A stock solution of diclofenac sodium (1,000 µg/mL) was 
prepared in a 50:50 (v/v) mixture of methanol and HPLC 
water. External standard calibration solutions were prepared 
by dilution of the stock solution with the 50:50 (v/v) mixture 
of methanol and HPLC water to produce solutions with 
Table S1 Parameters of the chromatographic measurement
Mobile phase Mixture of methanol and PBS buffer
ph 2.5
Flow rate 1 ml/min
injection volume 20 µl
elution type gradient elution
Detection wavelength 254 nm
column Kromasil 100 5c18, 5 µm 250×4.6 mm
Temperature 35°c
evaluation External standard calibration, 6 conc (n=3)
Time 20 min
Abbreviation: conc, concentrations.
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electroporation-enhanced transdermal diclofenac sodium delivery
concentrations of 0 (as blank), 10, 20, 50, 100, and 150 µg/mL 
(six standard solutions).
sample extraction procedure
An aliquot of plasma (1 mL) was combined with 100 µL 
of the internal standard solution (added amount 1.25 µg). 
The sample was acidified by adding 2 mL of 0.83 M phos-
phoric acid and 4 mL of hexane isopropyl alcohol (90:10). 
The mixtures were shaken for 10 min on a rotating shaker 
at 250 rpm and then centrifuged at 1,500 g for 10 min. 
The aqueous phase was frozen, and the organic phase was 
transferred to another tube and evaporated to dryness with 
nitrogen gas at room temperature. The dried residue was 
reconstituted with 300 µL of mobile phase and shaken for 
15 s on a vortex mixer, and then a 20 µL aliquot was injected 
into the HPLC system.
An aliquot of 1.2 mL of synovial fluid was added to 2 mL 
of orthophosphoric acid (0.83 M) and 0.6 mL of isopropyl 
alcohol and vortexed for a few seconds. After that, 5.4 mL 
of n-hexane was added, and the mixture was centrifuged at 
9,000 g for 5 min. The organic phase was transferred to a 
clean tube, and the solvent was evaporated to dryness with 
nitrogen gas at 30°C. The residue was dissolved in 1.2 mL 
of the mobile phase by vortexing. An aliquot of 20 µL was 
injected into the chromatograph.
linearity
Linearity was studied by preparing standard solutions in 
the range of 0–150 µg mL-1 (n=6), plotting a graph of con-
centration against area under the curve and determining the 
linearity. Two methods (the short and long methods) were 
compared to choose the optimal one for the HPLC analysis 
(Table S2).
Based on the linearity test and the low relative standard 
deviation % values, the short method is recommended. 
The advantage is a runtime shortened by 42% (35–20 min; 
Figure S2).
Table S2 comparison of the parameters of the long and short methods
Parameters of the HPLC method Long method Short method
linear regression equation y =20.491x -7.4762 Y =20.338x -1.9623
Coefficient of determination R2=0.9999 R2=0.9999
number of samples n=15 n=15
runtime (min) 35 20
rTDs (min), mean ± standard deviation 18.721±0.054 14.610±0.002
rsD – rTDs (%) 0.29 0.02
rsD – aUc (%) 1.70 1.52
rsD – maximum limit (%) 2.00 2.00
Abbreviations: aUc, area under the curve; hPlc, high-performance liquid chromatography; rsD, relative standard deviation; rTDs, residence time distributions.
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Figure S1 gastric adverse effects of diclofenac intake.
Notes: The effects of diclofenac treatment on the gastric mucosa. (A) Diclofenac treatment-induced gastric adverse effects. scale bars represent 10 mm. Black arrows show 
edema, irritation, and petechia formation. (B) Mean area of gastric lesions. The white column represents the control group (per os saline-treated), and the black column 
represents the per os diclofenac-treated group. The pale and dark columns (not visible, as values are 0.000) represent the topical and eP-combined topical diclofenac-treated 
groups, respectively. Data are presented as means ± sD. *p,0.05 vs per os diclofenac-treated group (Kruskal–Wallis one-way analysis and Dunnet test).
Abbreviations: eP, electroporation; sD, standard deviation of the mean.
Figure S2 The flow curve of the diclofenac sodium-containing hydrogel.
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